Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Medinger, Michael  [Clear All Filters]
2016
Baumgartner A, Zueger N, Bargetzi A, Medinger M, Passweg JR, Stanga Z, Mueller B, Bargetzi M, Schuetz P. Association of Nutritional Parameters with Clinical Outcomes in Patients with Acute Myeloid Leukemia Undergoing Haematopoietic Stem Cell Transplantation. Ann Nutr Metab. 2016;69(2):89-98.
Medinger M, Heim D, Gerull S, Halter J, Krenger W, Buser A, Lengerke C, Bucher C, Passweg J. Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Leuk Res. 2016;47:22-25.
Medinger M, Lengerke C, Passweg J. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer Genomics Proteomics. 2016;13(5):317-329.
2018
Kuster S, Stampf S, Gerber B, Baettig V, Weisser M, Gerull S, Medinger M, Passweg J, Schanz U, Garzoni C, et al. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation: A Swiss Transplant Cohort Study. Transpl Infect Dis. 2018:e12981.
Medinger M, Passweg J. What the internist should know about stem cell transplant in the elderly patient. Eur J Intern Med. 2018.
2019
Karakioulaki M, Martinez M, Medinger M, Heim D, Passweg JR, Tsakiris DA. Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. Int J Lab Hematol. 2019.
2022
Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, et al. Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2022.
2023
Dertschnig S, Passweg J, Bucher C, Medinger M, Tzankov A. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation. Cell Immunol. 2023;388-389:104719.
Ben Hassine K, Seydoux C, Khier S, Daali Y, Medinger M, Halter J, Heim D, Chalandon Y, Schanz U, Nair G, et al. Pharmacokinetic modeling and simulation with pharmacogenetic insights support the relevance of therapeutic drug monitoring for myeloablative busulfan dosing in adult HSCT. Transplant Cell Ther. 2023.